Related Experiment Video
Updated: Jan 15, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Triple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects
Valeriia Lebedeva1,2, Mira Ebbinghaus1, José Villacorta Hidalgo1
1Research and Development Department, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Abstract:
Triple-negative breast cancer (TNBC) has historically been challenging to treat due to limited therapeutic options. Since 2018, the treatment landscape has evolved substantially with the approval of precision therapies, including immune checkpoint inhibitors, poly (ADP-ribose) polymerase inhibitors, and antibody-drug conjugates. Despite these advancements, the therapeutic benefit remains limited due to various clinical challenges, largely driven by TNBC heterogeneity and an incomplete understanding of drug-tumor crosstalk mechanisms-both contributing to a restricted pool of eligible patients and variable treatment responses. Concurrently, emerging drugs tested in recent pivotal TNBC trials have demonstrated variable outcomes. Additionally, the associated economic burden has become a pressing global concern, as several approved drugs provide insufficient clinical benefit in relation to high expenditures, often driven by drug pricing. The situation is particularly critical in low- and middle-income countries, where TNBC is highly prevalent, yet access to even chemotherapeutic treatment remains limited. These factors collectively hinder real-world patient outcomes. This review provides a comprehensive analysis of TNBC management, integrating clinical advancements with economic perspectives and raising awareness of underdiscussed topics. The overview presented herein highlights the necessity for a global, interdisciplinary approach and patient centered care in TNBC drug development.
Insights
Triple-negative breast cancer (TNBC) treatment has advanced with new therapies, but challenges like heterogeneity and cost limit patient benefit. Global collaboration and patient-centered care are crucial for future drug development.
Area of Science:
- Oncology
- Pharmacology
- Health Economics
Background:
- Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its heterogeneity and limited treatment options.
- Recent approvals of precision therapies like immune checkpoint inhibitors and PARP inhibitors have improved outcomes but not universally.
- Variable patient responses and high drug costs impact real-world effectiveness, especially in low- and middle-income countries.
Purpose of the Study:
- To provide a comprehensive review of current TNBC management strategies.
- To integrate clinical advancements with economic considerations in TNBC treatment.
- To highlight unmet needs and future directions in TNBC drug development.
Main Methods:
- Literature review of recent clinical trials and therapeutic approvals for TNBC.
- Analysis of economic factors influencing TNBC treatment accessibility and cost-effectiveness.
- Synthesis of data to identify challenges and opportunities in TNBC management.
Main Results:
- Despite progress, TNBC heterogeneity and drug-tumor interactions limit treatment efficacy and patient eligibility.
- Emerging TNBC drugs show variable outcomes, and high costs pose a significant barrier, particularly in resource-limited settings.
- Existing treatments often provide insufficient clinical benefit relative to their high expenditure.
Conclusions:
- A global, interdisciplinary approach is essential for advancing TNBC drug development.
- Patient-centered care and improved access to effective therapies are critical for addressing the TNBC burden.
- Further research is needed to understand TNBC heterogeneity and optimize treatment strategies for diverse populations.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...